Prolensa is a prescription NSAID ophthalmic solution containing bromfenac 0.07%, FDA-approved in 2011 for reducing inflammation and pain after cataract surgery. Manufactured by Bausch & Lomb, it requires just one daily application and is available by prescription only from an ophthalmologist.
Clinical trial data show 78.3% of Prolensa patients were pain-free by day one after surgery. The drug blocks prostaglandin synthesis through COX-1 and COX-2 inhibition. It reduces cystoid macular edema incidence from 8% down to under 2%. Surgeons combine it with steroid drops for synergistic anti-inflammatory coverage throughout recovery.
This review covers how Prolensa works, what side effects patients experience, what reviewers report, and how it compares to generic alternatives. Cost ranges widely from $30 (generic bromfenac) to $400 (brand, no insurance). Pricing is the central question for many patients comparing their options.
What Are Prolensa Eye Drops?
Prolensa is a prescription NSAID ophthalmic solution containing bromfenac 0.07%, approved by the FDA to reduce inflammation and pain after cataract surgery. Manufactured by Bausch & Lomb, it’s distinguished from older NSAID drops by requiring just one application per day.
Here’s the thing: Prolensa belongs to the nonsteroidal anti-inflammatory drug class and is available only through a prescription from an ophthalmologist. No over-the-counter version exists. The once-daily format directly addresses one of the most common barriers to post-surgical compliance — a complex, multi-drop daily schedule.
The manufacturer distributes Prolensa through standard pharmacy channels in the United States. Patients fill the prescription at a local or mail-order pharmacy before their scheduled surgery date. The treating surgeon typically provides the prescription at the pre-operative visit.
Key Facts About Prolensa:
- Active ingredient: bromfenac sodium 0.07%
- Drug class: Nonsteroidal anti-inflammatory drug (NSAID)
- Manufacturer: Bausch & Lomb
- FDA approval year: 2011
- Dosing frequency: Once daily
- Prescription required: Yes
What Is the Active Ingredient in Prolensa?
Bromfenac sodium is the active ingredient in Prolensa, formulated at a concentration of 0.07% in a sterile ophthalmic solution. This specific concentration is what distinguishes Prolensa from other bromfenac products on the market.
In fact, bromfenac belongs to the phenylacetic acid subclass of NSAIDs and is structurally related to diclofenac. The molecule was specifically developed for ophthalmic use. The result is a drug that penetrates corneal tissue effectively at lower concentrations than earlier NSAID formulations required.
How Does Prolensa Work in the Eye?
Bromfenac inhibits cyclooxygenase enzymes COX-1 and COX-2 and blocks prostaglandin synthesis in ocular tissue. Prostaglandins are the chemical mediators responsible for post-surgical inflammation, pain, and increased vascular permeability in the eye.
Here’s what that means practically: after topical application, the drug penetrates the cornea and reaches therapeutic concentrations in the aqueous humor within one to two hours. The 0.07% formulation achieves adequate tissue levels with just a single daily drop.
The anti-inflammatory effect begins within hours of the first application. So surgeons start dosing one day before surgery. That pre-loading strategy establishes meaningful drug levels in the ocular tissues before any surgical trauma occurs.
What Is Prolensa Used For?
Prolensa is FDA-approved specifically for the treatment of postoperative inflammation and reduction of ocular pain following cataract extraction. That’s its primary and officially approved indication.
Some ophthalmologists use bromfenac off-label for other intraocular surgeries or chronic ocular surface inflammatory conditions. To be clear: these off-label applications are not supported by FDA approval. They reflect individual clinical judgment. Patients should follow the specific instructions given by their own surgeon, not general guidance.
Does Prolensa Reduce Pain After Cataract Surgery?
Yes. Prolensa demonstrated statistically significant reduction in ocular pain scores versus placebo starting from day one after cataract surgery in phase 3 clinical trials. The pain relief is measurable and clinically meaningful.
Here’s the data: phase 3 trial results showed 78.3% of Prolensa-treated patients were free of ocular pain at day one, compared to 55.8% in the vehicle group. That’s a 22.5 percentage point advantage. In the earliest, most uncomfortable phase of surgical recovery, that difference matters.
Does Prolensa Prevent Macular Edema?
Prolensa reduces prostaglandin-mediated vascular permeability in the retina, directly targeting the mechanism behind cystoid macular edema (CME) after cataract surgery. CME is a known complication that can seriously impair visual recovery.
The numbers are compelling. Multiple clinical studies show topical NSAIDs like bromfenac reduce pseudophakic CME incidence from approximately 8% without treatment to under 2% with treatment. That’s a six-percentage-point reduction. It translates to significantly fewer patients experiencing delayed or impaired visual recovery.
Surgeons frequently combine Prolensa with topical corticosteroid drops for enhanced CME prevention. And here’s why: the two drug classes work through different anti-inflammatory pathways. The combination produces a synergistic protective effect that neither drug achieves alone. That’s now the standard of care in most ophthalmic practices.
How Do You Use Prolensa Eye Drops?
Prolensa is administered as one drop in the operative eye once daily. The regimen starts one day before cataract surgery and runs for two weeks after the procedure. The dropper tip should never touch the eye or any surface.
The standard regimen spans approximately 15 to 16 days total: one dose the day before surgery, one dose on surgery day, and fourteen doses during the post-operative weeks. Sticking to that schedule matters. It maintains consistent anti-inflammatory drug levels throughout the entire healing period.
Standard Prolensa Dosing Schedule:
- Day before surgery: Apply one drop to the operative eye.
- Day of surgery: Apply one drop to the operative eye.
- Days 1-14 after surgery: Apply one drop each day at the same time.
- Discard the bottle 28 days after opening.
What Is the Correct Prolensa Dosage?
The FDA-approved dose of Prolensa is one drop of the 0.07% solution (approximately 35 micrograms of bromfenac) in the operative eye once daily. No dose adjustment has been established for elderly patients, children, or those with kidney or liver impairment.
Missed a dose? Apply it as soon as it’s remembered on the same day. The next drop should not be doubled. Taking two drops at once doesn’t improve outcomes. It may actually increase the risk of local adverse effects.
Prolensa should be stored at room temperature between 15 and 25 degrees Celsius (59 to 77 degrees Fahrenheit), away from direct light. The bottle must be discarded 28 days after opening, regardless of remaining volume, to prevent contamination.
Can You Use Prolensa With Other Eye Drops?
Prolensa can be used with other topical ophthalmic medications, but patients must wait at least five minutes between each drop to prevent dilution and ensure full absorption. Drop them too close together and the therapeutic effect of each medication drops significantly.
Surgeons routinely combine Prolensa with steroid eye drops such as prednisolone acetate or difluprednate after cataract surgery. The two classes of anti-inflammatory drugs work through complementary pathways. That combination provides broader protection against post-surgical complications than either drug alone.
Here’s an important restriction: patients should not wear soft contact lenses while using Prolensa. The preservative benzalkonium chloride in the formulation absorbs into soft lens material. It can then concentrate on the ocular surface, potentially causing chronic irritation and epithelial damage with repeated exposure.
What Are the Side Effects of Prolensa?
Prolensa has a generally well-tolerated safety profile, with adverse events occurring in a small minority of patients and most effects being mild and temporary. Serious complications are rare when the drug’s used as directed for the recommended duration.
The most frequently reported adverse reactions include eye irritation, burning or stinging upon instillation, eye redness, and a foreign body sensation. These effects are consistent with the known tolerability profile of topical NSAID eye drops as a class.
Prolensa Side Effects by Frequency:
| Side Effect | Frequency | Severity |
| Eye irritation | 8.5% | Mild |
| Ocular hyperemia (redness) | 5.5% | Mild |
| Eye pain / iritis | Less than 5% | Mild to moderate |
| Foreign body sensation | Less than 5% | Mild |
| Corneal adverse events | Rare | Serious |
What Are the Common Prolensa Side Effects?
Common side effects of Prolensa reported in clinical trials include eye irritation in approximately 8.5% of patients, ocular hyperemia in 5.5%, and eye pain or iritis in smaller percentages. Most resolve on their own without intervention.
Many patients report a mild burning or stinging sensation immediately after applying the drop. The sensation typically lasts only a few seconds. Most users find it diminishes as the treatment course continues. A minority experiences persistent discomfort throughout the entire two-week period.
Are There Serious Risks With Prolensa?
Serious corneal adverse events, including keratitis, corneal erosion, and corneal thinning, represent rare but real risks associated with topical NSAID use, including Prolensa, particularly with prolonged application beyond the prescribed duration. These aren’t common with standard two-week use.
NSAIDs including bromfenac can slow normal wound healing. They also inhibit platelet aggregation, potentially increasing bleeding time in ocular tissues following surgery. Patients already on systemic anticoagulants or who have bleeding disorders face elevated risk. They should inform their surgeon before use.
And here’s one that surprises some patients: Prolensa contains sodium sulfite, a preservative that can trigger allergic-type reactions including anaphylaxis in susceptible individuals. Anyone with a known sulfite sensitivity should disclose it to their ophthalmologist before the prescription is written.
Who Should Use Prolensa With Caution:
- Patients with aspirin or NSAID hypersensitivity
- Those on blood thinners or anticoagulant therapy
- Patients with diabetes or rheumatoid arthritis
- Individuals with known sulfite allergy
- Pregnant patients, especially in the third trimester
What Do Prolensa Reviews Say?
Prolensa receives an average rating of approximately 7 to 8 out of 10 from patients on pharmacy review platforms, reflecting general satisfaction with its performance after cataract surgery. The majority of reviewers report effective pain and inflammation control.
Patients most frequently praise Prolensa’s once-daily dosing, describing it as a meaningful convenience advantage over older post-surgical drop regimens. Effective pain control within the first day of use is another attribute that patients consistently highlight across multiple review platforms.
What Do Patients Say About Prolensa?
Many patients report that Prolensa effectively controlled post-surgical inflammation and enabled a faster return to normal daily activities than they anticipated after cataract surgery. Smooth, steady visual recovery is the recurring theme in positive reviews.
Patients using Prolensa as part of a combination regimen with steroid drops describe recovery as manageable and straightforward. Most report that visual clarity improved steadily throughout the two-week treatment window. The single daily dose is consistently described as easy to remember. It fits naturally into a morning routine.
What Are the Common Complaints About Prolensa?
The most common complaint about Prolensa is its high retail cost, which ranges from $200 to $400 (USD) per bottle without insurance. That makes it one of the more expensive post-surgical eye drops available by prescription.
Some users report persistent stinging or burning upon instillation that bothers them throughout the full treatment course. For most, the discomfort is mild. A smaller subset finds it uncomfortable enough to discuss switching to an alternative formulation with their surgeon after the first few days.
Bottom line on the third complaint: insurance access is a real barrier. Many health plans require prior authorization or mandate a trial of a lower-cost alternative before approving Prolensa. These formulary hurdles create delays and administrative friction for patients who need the drops before a scheduled surgery date.
Prolensa Reviews Summary:
| Category | Patient Sentiment |
| Pain control effectiveness | Positive |
| Inflammation reduction | Positive |
| Dosing convenience | Positive |
| Cost without insurance | Negative |
| Insurance access / formulary | Negative |
| Instillation comfort | Mixed |
How Does Prolensa Compare to Other NSAID Eye Drops?
Prolensa requires once-daily dosing, giving it a significant convenience advantage over ketorolac (four times daily) and Nevanac (three times daily), while matching Ilevro and Bromday on dosing frequency. The key differentiators among once-daily options are cost, concentration, and tolerability.
Head-to-head studies comparing bromfenac to ketorolac show comparable anti-inflammatory efficacy in reducing post-cataract inflammation. So what does that mean for the choice? The clinical decision often comes down to patient preference, insurance coverage, and the prescribing surgeon’s experience with each formulation.
NSAID Eye Drop Comparison:
| Drug | Active Ingredient | Dosing | Concentration |
| Prolensa | Bromfenac | Once daily | 0.07% |
| Bromday / Generic | Bromfenac | Once daily | 0.09% |
| Ilevro | Nepafenac | Once daily | 0.3% |
| Nevanac | Nepafenac | Three times daily | 0.1% |
| Ketorolac | Ketorolac | Four times daily | 0.5% |
Prolensa vs. Ilevro: Which Is Better?
Prolensa contains bromfenac 0.07% (an active NSAID) while Ilevro contains nepafenac 0.3%, a prodrug that the eye converts to amfenac inside ocular tissues after absorption. Both are once-daily formulations with similar anti-inflammatory goals.
Clinical studies comparing bromfenac and nepafenac show similar outcomes for post-cataract inflammation control. Ophthalmologists generally choose between the two based on patient response, individual tolerability, and insurance formulary placement. There’s no clear, consistent efficacy winner between the two in the literature.
Here’s the good news for budget-conscious patients: generic bromfenac 0.09% (the Bromday formulation) is available at significantly lower cost than branded Prolensa, often $30 to $60 (USD) with discount programs. It’s not identical in concentration to Prolensa, but most insurance payers and many ophthalmologists consider it therapeutically equivalent.
How Much Does Prolensa Cost?
The average retail price of Prolensa without insurance is $250 to $400 (USD) for a 1.6 mL bottle, placing it among the highest-priced postoperative eye drops in the NSAID category. Most patients need only one bottle per eye treated.
With prescription insurance coverage, the typical copay for Prolensa falls between $30 and $90 (USD) depending on the plan tier. Many Medicare Part D plans place Prolensa on a specialty or non-preferred tier. That means higher cost-sharing even with active coverage.
Is Prolensa Worth the Price?
For patients with good insurance coverage, Prolensa offers strong clinical value through its once-daily convenience, proven efficacy, and well-documented safety profile across two FDA phase 3 trials. The cost burden drops substantially with coverage.
Budget-conscious patients have a workable alternative. Generic ketorolac costs approximately $15 to $25 (USD) per bottle but requires four daily applications. The good news? Most surgeons are willing to substitute a generic NSAID when cost is a barrier, with comparable therapeutic outcomes for the majority of patients.
Is There a Generic Version of Prolensa?
A direct generic of Prolensa (bromfenac 0.07%) is not currently available, but generic bromfenac 0.09% is sold at significantly lower cost and is considered therapeutically equivalent by most payers. It’s the closest alternative available.
Generic bromfenac 0.09% can cost as low as $30 to $60 (USD) per bottle through discount programs such as GoodRx. Patients considering the switch should discuss the concentration difference with their surgeon first. The prescribing physician should be aware of any formulation change during post-surgical recovery.
Prolensa Cost Comparison:
| Option | Average Cost (USD) | Dosing |
| Prolensa (brand, no insurance) | $250-$400 | Once daily |
| Prolensa (with insurance copay) | $30-$90 | Once daily |
| Generic bromfenac 0.09% | $30-$60 | Once daily |
| Generic ketorolac 0.5% | $15-$25 | Four times daily |
Is Prolensa Safe to Use?
Yes. Prolensa received FDA approval in April 2011 following two randomized, double-masked, vehicle-controlled phase 3 clinical trials that confirmed both its safety and efficacy for post-cataract use. The regulatory review established a favorable benefit-risk profile.
Patients with known hypersensitivity to bromfenac or other NSAIDs should not use Prolensa. Caution is also warranted in patients with bleeding disorders, those on systemic anticoagulant therapy, and individuals with conditions that impair wound healing such as diabetes or rheumatoid arthritis. Surgeons routinely screen for these factors before prescribing.
Here’s an important caution: Prolensa carries a specific warning for use during the third trimester of pregnancy. As with other NSAIDs, systemic absorption from topical ophthalmic use raises concern for premature closure of the fetal ductus arteriosus. Pregnant patients should discuss timing and alternatives with both their obstetrician and ophthalmologist before surgery is scheduled.
Is Prolensa Worth It?
Prolensa is a clinically effective, FDA-approved NSAID eye drop with strong phase 3 trial data supporting its use for post-cataract inflammation and pain. It is a reliable choice when prescribed by an ophthalmologist.
The drops are best suited for patients recovering from cataract surgery who have prescription coverage and want the convenience of a once-daily regimen. For patients without insurance or on a tight budget, generic alternatives offer comparable therapeutic benefit at a fraction of the cost. That conversation belongs between the patient and their surgeon.
Bottom line: Prolensa works. The efficacy data is solid, the safety record is established, and the once-daily format reduces the daily drop burden during an already stressful recovery period. Cost is the primary reason some patients and surgeons reach for alternatives.